GlaxoSmithKline stopped a company from using “GSK” for pharmaceutical products and won a permanent injunction. But it walked away without a rupee in punitive damages — because it couldn’t put a figure on its loss. A clear lesson: damages need evidence, not just a strong case.
The dispute
The plaintiffs — GlaxoSmithKline Pharmaceuticals and SmithKline Beecham (the GSK Group) — are Indian market leaders behind CALPOL, CROCIN, ENO, HORLICKS, AQUAFRESH, SENSODYNE and more, using the acronym “GSK” since 2000 and holding registered “GSK” marks. The defendant directed GSK Life Sciences Pvt Ltd, using “GSK” in its trade name and logo (per its representatives’ business cards) — allegedly a deceptively similar logo.
GSK sent a cease-and-desist (2013) and letters; the defendant claimed “GSK” was the initials of Gadikota Sarath Kumar Reddy. GSK alleged infringement under Section 29(5) and that “GSK” is a well-known mark (Sections 2(1)(zg)/11(6)).
The ruling
The defendant failed to appear, so the court passed an ex parte ad-interim injunction. On the merits, it found the defendant dealt in pharmaceutical products under “GSK,” and that GSK’s registered proprietorship meant incorporating “GSK” in the defendant’s corporate/trade name infringed. It cited Milmet Oftho v. Allergan:
“In respect of medicinal products… exacting judicial scrutiny is required if there was a possibility of confusion over marks… because the potential harm may be far more dire than… confusion over ordinary consumer products… confusion and mistakes could arise even for prescription drugs… physicians are not immune from confusion…”
The court granted a permanent injunction and ordered delivery-up of GSK-marked material.
Why punitive damages were denied
But GSK couldn’t quantify the loss the defendant caused, and no evidence of the defendant’s sales was before the court. So, restating that courts are stringent with punitive damages, the Delhi HC held the circumstances justifying them weren’t shown — and rejected the prayer.
Given GSK’s distinguished global and Indian reputation, punitive damages might have seemed fair — but the court preferred the evidentiary line: without a quantified loss or the infringer’s sales figures, no punitive award.
The takeaways
- Injunction ≠ automatic damages — GSK won the injunction but not punitive damages.
- Quantify the loss — courts need evidence of your loss and/or the infringer’s sales.
- Medicinal marks get exacting scrutiny — Milmet Oftho, given the dire potential harm.
- Punitive damages remain hard to get — reserved for shown, exceptional circumstances.
Frequently asked questions
Why were punitive damages denied to GSK despite winning? Because GSK couldn’t quantify its loss and there was no evidence of the defendant’s sales — so the circumstances justifying punitive damages weren’t shown.
Did GSK win the case? Yes — it obtained a permanent injunction against use of “GSK” and an order for delivery-up of infringing material; only punitive damages were refused.
Why do medicinal-product marks get stricter scrutiny? Per Milmet Oftho, confusion over medicinal marks can cause far more dire harm than ordinary products — even prescription drugs risk pharmacist/physician confusion.
What do I need to recover punitive damages? Evidence — a quantified loss and/or the infringer’s sales figures — plus circumstances (like wilful conduct) that justify going beyond compensation.
Legislation referred to
- The Trade Marks Act, 1999